PDF DatasheetHuman Anti-TRIM29 Antibody Product Attributes
TRIM29 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-TRIM29 antibody staining is expected to be primarily localized to the intermediate filaments and nucleoplasm.
Observed Antibody Staining Data By Tissue Type:
Variations in TRIM29 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in squamous epithelial cells in the cervix, uterine and esophagus, respiratory epithelial cells in the nasopharynx, squamous epithelial cells in the oral mucosa, keratinocytes in skin, melanocytes in skin, epidermal cells in the skin and squamous epithelial cells in the tonsil and vagina. More moderate antibody staining intensity was present in squamous epithelial cells in the cervix, uterine and esophagus, respiratory epithelial cells in the nasopharynx, squamous epithelial cells in the oral mucosa, keratinocytes in skin, melanocytes in skin, epidermal cells in the skin and squamous epithelial cells in the tonsil and vagina. Low, but measureable presence of TRIM29 could be seen inmyoepithelial cells in the breast, glandular cells in the epididymis and fallopian tube, pneumocytes in lung, decidual cells in the placenta and trophoblastic cells in the placenta. We were unable to detect TRIM29 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of TRIM29 expression as measured by anti-TRIM29 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | ++ | + | – | – | ++ | + | ++ | – | – | – | – | – | – | +++ | – | – | – | ++ |
| TRIM29 Variability | + | + | ++ | ++ | + | + | ++ | +++ | ++ | + | + | ++ | ++ | + | + | ++ | + | + | + | +++ |
| TRIM29 General Information | |
|---|---|
| Alternate Names | |
| Tripartite motif-containing protein 29, TRIM29 | |
| Molecular Weight | |
| 66kDa | |
| Chromosomal Location | |
| 11q23.3 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | TRIM29 |
| Entrez Gene ID | 23650 |
| Ensemble Gene ID | ENSG00000137699 |
| RefSeq Protein Accession(s) | XP_011541035, NP_036233, XP_011541034, XP_011541031, XP_005271547, XP_016872942, NP_001317311, XP_016872943 |
| RefSeq mRNA Accession(s) | NM_012101, XM_005271490, XM_011542732, XM_017017453, NM_058193, XM_011542729, XM_011542733, NM_001330382, XM_017017454 |
| RefSeq Genomic Accession(s) | NC_000011, NC_018922 |
| UniProt ID(s) | Q14134, A0A024R3J1, B7Z5V5, E9PRL4, B7Z8U9 |
| UniGene ID(s) | Q14134, A0A024R3J1, B7Z5V5, E9PRL4, B7Z8U9 |
| HGNC ID(s) | 17274 |
| Cosmic ID(s) | TRIM29 |
| KEGG Gene ID(s) | hsa:23650 |
| PharmGKB ID(s) | PA38218 |
| General Description of TRIM29. | |
| It recognizes a 66kDa protein, which is identified as Tripartite motif-containing protein 29 (TRIM29). It interacts with the intermediate filament protein vimentin, a substrate for the PKC family of protein kinases,, with hPKCI-1, an inhibitor of the PKCs. TRIM29 protein contains both zinc finger, leucine zipper motifs, suggesting that the it may form homodimers, possibly associate with DNA. High expression of TRIM29 has been reported in gastric cancer, pancreatic cancer,, correlates with enhanced tumor growth, lymph node metastasis. TRIM29 is also able to distinguish lung squamous cell carcinoma from lung adenocarcinoma with ~90% positive accuracy, when used in a panel with TTF-1, p63, CK5/6,, Napsin-A antibodies. | |
There are no reviews yet.